Pharma stock jumps after it acquires 85.6% stake in Amplitude Surgical SA, France
News by Aliceblue News Desk
11 Mar 2025
Introduction:
Leading pharma company has entered exclusive negotiations to acquire an 85.6% stake in Amplitude Surgical, France, for €256.8 million. This strategic move aims to expand its global footprint in the surgical sector, strengthening its presence in the European market.
Share price movement of Zydus Lifesciences:
On March 11, 2025, Zydus Lifesciences Ltd opened at ₹892.80, down 0.81% from its previous close of ₹893.20. The stock reached a high of ₹904.55 (1.27%) and a low of ₹883.55. By 2:41 PM, it traded at ₹900.45, a 0.81% increase, with a market cap of ₹90,606.34 crore.
Zydus Enters Exclusive Talks to Acquire Amplitude Surgical:
Zydus has entered exclusive negotiations with PAI Partners and other shareholders to acquire an 85.6% stake in Amplitude Surgical, France. The deal is valued at €256.8 million, with each share priced at €6.25.
Following the acquisition of the controlling stake, Zydus will initiate a mandatory simplified cash tender offer for the remaining shares at the same price. If the required conditions are met, the company intends to execute a squeeze-out process to delist Amplitude Surgical from the stock exchange.
This strategic move will strengthen Zydus global presence in the surgical and orthopedic sector. The acquisition aligns with its expansion plans and enhances its expertise in the European market. Completion of the transaction is subject to regulatory approvals and closing formalities.
Recent news on Zydus Lifesciences:
As of February 14, 2025, Zydus Lifesciences Ltd announced that the USFDA completed an inspection at its Ahmedabad facility with nil observations. The company reported a 30% YoY rise in Q3 FY25 net profit to ₹1,023 crore, reflecting strong growth.
Stock performance of Zydus Lifesciences for Period of 1 week, 6 months, and 1 year:
Zydus Lifesciences Ltd delivered a 2.53% gain over the past week but faced a 20.2% decline in six months and a 10.1% drop over the past year, reflecting short-term recovery amid long-term challenges in stock performance.
Also Read: Infra stock jumps after receiving LoA worth ₹311 Cr from Maharashtra State Electricity Transmission
Shareholding pattern of Zydus Lifesciences:
| Particulars | Dec 2024 | Sep 2024 | Jun 2024 |
| Promoter | 75.00% | 75.00% | 75.00% |
| FII | 7.50% | 7.50% | 5.60% |
| DII | 10.70% | 10.60% | 12.60% |
| Public | 6.90% | 7% | 7% |
About Zydus Lifesciences:
Zydus Lifesciences Ltd (NSE: ZYDUSLIFE), established in 1995, evolved from Cadila Healthcare. Growing from ₹250 crore revenue to ₹14,253 crore in FY20, the company remains committed to innovation, addressing healthcare needs, and improving global well-being.
Disclaimer: The above article is written for educational purposes, and the companies’ data mentioned in the article may change with respect to time. The securities quoted are exemplary and are not recommendatory.
News Author
Aliceblue News Desk
